\BOOKMARK [0][-]{chapter.1}{Transcription}{}% 1
\BOOKMARK [1][-]{section.1.1}{Transcription initiation}{chapter.1}% 2
\BOOKMARK [1][-]{section.1.2}{Chromatin remodeling}{chapter.1}% 3
\BOOKMARK [1][-]{section.1.3}{Nucleosome organization}{chapter.1}% 4
\BOOKMARK [2][-]{subsection.1.3.1}{Nucleosome remodelling}{section.1.3}% 5
\BOOKMARK [2][-]{subsection.1.3.2}{Chromatin Immunoprecipitation}{section.1.3}% 6
\BOOKMARK [2][-]{subsection.1.3.3}{Main nucleosome modifications in promoters:}{section.1.3}% 7
\BOOKMARK [1][-]{section.1.4}{Transcription elongation}{chapter.1}% 8
\BOOKMARK [2][-]{subsection.1.4.1}{Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018}{section.1.4}% 9
\BOOKMARK [1][-]{section.1.5}{Transcription termination}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.5.1}{Promoter reporter assay}{section.1.5}% 11
\BOOKMARK [2][-]{subsection.1.5.2}{Promoter types}{section.1.5}% 12
\BOOKMARK [2][-]{subsection.1.5.3}{Transcription factor binding}{section.1.5}% 13
\BOOKMARK [0][-]{chapter.2}{Transcription regulation and its deregulation in cancer}{}% 14
\BOOKMARK [1][-]{subsection.2.0.1}{Wnt signalling pathway}{chapter.2}% 15
\BOOKMARK [1][-]{section.2.1}{6- Transcriptional Control in Cancer}{chapter.2}% 16
\BOOKMARK [1][-]{section.2.2}{CREP/p300}{chapter.2}% 17
\BOOKMARK [2][-]{subsection.2.2.1}{TSSa-RNAs transcription}{section.2.2}% 18
\BOOKMARK [0][-]{chapter.3}{Chromsome domains and oncogene activation}{}% 19
\BOOKMARK [1][-]{section.3.1}{7- Transcriptional Control in Cancer}{chapter.3}% 20
\BOOKMARK [2][-]{subsection.3.1.1}{Super-enhancers}{section.3.1}% 21
\BOOKMARK [1][-]{section.3.2}{How is a SE generated during tumorigenesis?}{chapter.3}% 22
\BOOKMARK [2][-]{subsection.3.2.1}{How cancer cells take advantage of super-enhancers}{section.3.2}% 23
\BOOKMARK [1][-]{section.3.3}{The role of MYC in cancer cells}{chapter.3}% 24
\BOOKMARK [2][-]{subsection.3.3.1}{Key aspect of MYC in tumorigenesis}{section.3.3}% 25
\BOOKMARK [2][-]{subsection.3.3.2}{By which major mechanism or pathway MYC proteins promote tumorigenesis?}{section.3.3}% 26
\BOOKMARK [0][-]{chapter.4}{Targeting transcription in cancer}{}% 27
\BOOKMARK [1][-]{subsection.4.0.1}{Target transcription in cancer}{chapter.4}% 28
\BOOKMARK [1][-]{section.4.1}{15- Transcriptional Control in Cancer}{chapter.4}% 29
\BOOKMARK [1][-]{section.4.2}{BRD4}{chapter.4}% 30
\BOOKMARK [1][-]{section.4.3}{YAP/TAZ}{chapter.4}% 31
\BOOKMARK [1][-]{section.4.4}{TEAD}{chapter.4}% 32
\BOOKMARK [2][-]{subsection.4.4.1}{YAP/TAZ/TEAD}{section.4.4}% 33
\BOOKMARK [1][-]{section.4.5}{17- Transcriptional Control in Cancer}{chapter.4}% 34
\BOOKMARK [1][-]{section.4.6}{Nuclear receptors}{chapter.4}% 35
\BOOKMARK [2][-]{subsection.4.6.1}{Estrogen receptor \134alpha}{section.4.6}% 36
\BOOKMARK [2][-]{subsection.4.6.2}{ER\) in breast cancer}{section.4.6}% 37
\BOOKMARK [0][-]{chapter.5}{Transcription and genome instability}{}% 38
\BOOKMARK [1][-]{subsection.5.0.1}{R-loops}{chapter.5}% 39
\BOOKMARK [2][-]{subsection.5.0.2}{HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{subsection.5.0.1}% 40
\BOOKMARK [2][-]{subsection.5.0.3}{HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{subsection.5.0.1}% 41
\BOOKMARK [1][-]{section.5.1}{20- Transcriptional Control in Cancer}{chapter.5}% 42
\BOOKMARK [1][-]{section.5.2}{Transcription and genome instability II}{chapter.5}% 43
\BOOKMARK [2][-]{subsection.5.2.1}{DNA damage}{section.5.2}% 44
\BOOKMARK [2][-]{subsection.5.2.2}{Apical kinases}{section.5.2}% 45
\BOOKMARK [2][-]{subsection.5.2.3}{Topoisomerases}{section.5.2}% 46
\BOOKMARK [0][-]{chapter.6}{Role of transcription in DNA damage response and repair}{}% 47
\BOOKMARK [1][-]{subsection.6.0.1}{Biogenesis of canonical miRNA}{chapter.6}% 48
\BOOKMARK [2][-]{subsection.6.0.2}{DICER and DROSH regulation of DDR and checkpoint enforcement}{subsection.6.0.1}% 49
\BOOKMARK [2][-]{subsection.6.0.3}{DDRNAs}{subsection.6.0.1}% 50
\BOOKMARK [2][-]{subsection.6.0.4}{RNA Pol II recruitment at DSBs}{subsection.6.0.1}% 51
\BOOKMARK [0][-]{chapter.7}{Telomeres and telomere transcription in cancer}{}% 52
\BOOKMARK [1][-]{subsection.7.0.1}{What are telomeres?}{chapter.7}% 53
\BOOKMARK [2][-]{subsection.7.0.2}{Telomere dysfunction in a p53 and Rb mutant setting does not induce cell cycle block}{subsection.7.0.1}% 54
\BOOKMARK [2][-]{subsection.7.0.3}{End of replication problem}{subsection.7.0.1}% 55
\BOOKMARK [2][-]{subsection.7.0.4}{Cell crisis}{subsection.7.0.1}% 56
\BOOKMARK [2][-]{subsection.7.0.5}{Telomerase enzyme}{subsection.7.0.1}% 57
\BOOKMARK [0][-]{chapter.8}{Journal Clubs}{}% 58
\BOOKMARK [1][-]{section.8.1}{11- JC Transcriptional Control in Cancer}{chapter.8}% 59
\BOOKMARK [2][-]{subsection.8.1.1}{MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation}{section.8.1}% 60
\BOOKMARK [2][-]{subsection.8.1.2}{BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer}{section.8.1}% 61
